SAN FRANCISCO and SUZHOU, China, May 25, 2025 /PRNewswire/ — Innovent Biologics (HKEX: 01801), a global biopharmaceutical leader in oncology, metabolic diseases, and autoimmune therapies, announced today that groundbreaking Phase 3 trial results for its dual glucagon/GLP-1 receptor agonist mazdutide were published in *The New England Journal of Medicine* (NEJM). The study, conducted in Chinese adults with overweight or obesity (GLORY-1), marks a pivotal moment for both the drug and China’s accelerating biotech sector.
Notably, this is the first NEJM publication for mazdutide—the world’s inaugural dual GCG/GLP-1 agonist nearing commercialization—and the first time a Chinese-developed metabolic therapy trial has been featured in the prestigious journal. Experts hailed the milestone as evidence of China’s rising prowess in global drug innovation, potentially reshaping clinical guidelines for obesity management.
In an accompanying NEJM editorial, Harvard Medical School’s Dr. Vanita R. Aroda and University of Colorado’s Dr. Leigh Perreault underscored the trial’s implications. They noted that younger Chinese populations exhibit metabolic risks comparable to older Western demographics, necessitating region-specific strategies. Mazdutide’s dual-action mechanism not only reduced body weight but also improved cardiovascular and liver health, positioning it as a holistic solution. “Earlier intervention in China’s obesity crisis is critical,” they emphasized, advocating for integrated public health and pharmacological approaches.
The 48-week GLORY-1 trial enrolled 610 participants (BMI ≥24 with comorbidities). At baseline, mean weight was 87.2 kg (BMI 31.1). By week 48, mazdutide 6 mg demonstrated a 14.84% mean weight reduction versus placebo’s 0.47%, with 50.6% achieving ≥15% weight loss. Secondary benefits included improved blood pressure, lipids, liver fat (-80.24% in high-baseline subgroups), and metabolic markers. Safety aligned with established GLP-1 therapies, with transient gastrointestinal events as the primary side effects.
Professor Linong Ji of Peking University, the study’s lead author, highlighted the urgency for China-centric obesity frameworks: “Global guidelines often overlook Asian profiles. Nearly half of our participants achieved >15% weight loss—a game-changer for severe cases.” Innovent’s Dr. Lei Qian added, “This publication validates China’s clinical research caliber. Mazdutide’s imminent launch could redefine standards under ‘Healthy China 2030.’”
Mazdutide, developed via a Lilly-partnered pipeline, targets both weight management and glycemic control, with six Phase 3 trials underway. FIERCE Pharma ranks it among 2025’s top 10 anticipated drugs, reflecting its blockbuster potential in China’s 600M+ overweight/obese population. Innovent plans additional studies in adolescent obesity, sleep apnea, and metabolic liver disease.
With dual NDAs under review in China and global partnerships spanning Eli Lilly to MD Anderson, Innovent continues to bolster its portfolio across oncology and metabolic diseases. As obesity-related deaths double in China since 1990, mazdutide’s launch could catalyze a new era of targeted, sustainable therapies.
SOURCE Innovent Biologics
View original content: https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/936.html
